From “More is Better” to “Less is More”: A Commentary on Antimicrobial Use in Pediatric Oncology

Abstract Reducing avoidable antimicrobial exposure to pediatric patients with cancer is achievable and necessary to promote optimal short- and long-term outcomes. Multiple evidence-based practices are already well established but should be more consistently implemented. Important opportunities exist to further improve the evidence to guide selective antimicrobial use in pediatric oncology. This commentary provides guidance to clinicians on specific opportunities and strategies to promote judicious antimicrobial use in pediatric oncology patients. Current best practices and research gaps are addressed from both infectious disease specialist and oncologist perspectives.